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Abstract: The medical profession is becoming ever more interested in the use of gas-phase biomarkers
for disease identification and monitoring. This is due in part to its rapid analysis time and low test
cost, which makes it attractive for many different clinical arenas. One technology that is showing
promise for analyzing these gas-phase biomarkers is the electronic nose—an instrument designed to
replicate the biological olfactory system. Of the possible biological media available to “sniff”, urine is
becoming ever more important as it is easy to collect and to store for batch testing. However, this
raises the question of sample storage shelf-life, even at ´80 ˝C. Here we investigated the effect of
storage time (years) on stability and reproducibility of total gas/vapour emissions from urine samples.
Urine samples from 87 patients with Type 2 Diabetes Mellitus were collected over a four-year period
and stored at ´80 ˝C. These samples were then analyzed using FAIMS (field-asymmetric ion mobility
spectrometry—a type of electronic nose). It was discovered that gas emissions (concentration and
diversity) reduced over time. However, there was less variation in the initial nine months of storage
with greater uniformity and stability of concentrations together with tighter clustering of the total
number of chemicals released. This suggests that nine months could be considered a general guide to
a sample shelf-life.
Keywords: urinary stability; storage; electronic nose; ion mobility spectrometry; headspace analysis
1. Introduction
There is an increasing medical interest in the detection and monitoring of gases and volatiles for
the identification and monitoring of disease. One technology that has shown promise in detecting these
gases and volatiles is the electronic nose. Since its invention in the 1980s [1] it has seen considerable
use with the medical field and has been applied to diseases as diverse as brain cancers to tuberculosis
and even wound monitoring [2–4]. Such instruments do not attempt to detect individual chemicals
in a sample but, like the biological nose, attempt to analyze a sample as a whole by using an array
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of non-selective chemical sensors. Its clinical diagnostic utility has a number of key advantages over
many other current techniques; it is a low-cost test, the liquid/solid phase sample does not need to
enter the instrument, there are no reagents involved and the results can be provided in almost real-time,
making it attractive as a future point-of-care tool [5–9].
Our group has shown the utility of the electronic nose to detect and monitor a range of
gastroenterological and metabolic disorders [10,11]. We have focused primarily on investigating
urine as the biological waste of choice, as it provides an integrated physiological signal that is stable,
can be provided on demand and, in our experience, is the most “user friendly” of biological samples for
both the patient and the investigation team when compared with blood, breath and faeces. However,
in ours and many other urinary based studies, it can be difficult to analyse chemical signals from
samples at the point of collection. The reasons for this are many, but usually due to a combination of
the disease having low-prevalence combined with the logistical advantages (in terms of time, money
and access to equipment) of batch processing. In this case freezing of the sample (normally at ´80 ˝C)
is undertaken. Thus an important question that has concerned us, and probably others, is “what is the
best before date for a urine sample?”. Due to the way in which electronic noses analyse samples, it is
very challenging to monitor the degradation of any specific biomarker. However, it should be possible
to be guided on what a sensible storage period might be by understanding the general loss of chemical
information (or by the way that the urine sample changes over time). Therefore, in this study we have
attempted to understand the stability and degradation of a urine samples, using the electronic nose as
the measurement technology.
Previous work for urine stability has focused almost solely in the liquid phase, applying
techniques such as NMR (nuclear magnetic resonance), GC-TOF-MS (gas chromatography-time of
flight-mass spectrometry) and LC-MS (liquid chromatography-mass spectrometry) to investigate this
problem [12–14]. However, as this does not employ headspace analysis (using an electronic nose
or other approach), its relevance is low. Other groups have also undertaken headspace analysis of
urine samples to investigate the natural variation by GCMS (gas chromatography/mass spectrometry)
and SIFT-MS (selective ion flow tube—mass spectrometry), but did not consider stability of their
samples [15,16]. There have been a small number of studies using GCMS investigating sample
age over 24 h in humans and in mice [17,18]. Yet, these studies do not consider long-term storage
and, more importantly for our studies, do not employ an electronic nose in their work. As the
electronic nose does not detect individual chemicals and the sensitivity/selectivity of the sensors
is very different—detecting both small molecular weight gases and large organics at the same time.
Therefore, we set out to understand the rate of urinary degradation at ´80 ˝C using the electronic nose
and from this infer when degradation of the sample becomes significant. To undertake this study urine
samples from patients with Type 2 Diabetes Mellitus (T2DM) were collected over a four and half year
period and stored at ´80 ˝C. Though diabetic samples were used in this study (due to availability),
it is likely that the overall degradation of urines from this group would be similar to other diseases.
These samples were then analyzed using by FAIMS (field-asymmetric ion mobility spectrometry), as a
type of electronic nose.
2. Materials and Methods
2.1. Patients
In diabetes mellitus, the deficiency of insulin alters the metabolism of carbohydrates, proteins
and lipids, resulting in high glucose levels present in urine. Patients with type 2 diabetes (T2DM)
were recruited from the metabolic clinic at University Hospital Coventry and Warwickshire (UHCW)
NHS Trust between December 2009 and May 2014. In total, 87 samples were obtained over 53 months
and tested as single batch of samples in May 2014 over the course of two weeks. The only criterion
for inclusion was T2DM as defined by WHO criteria. Exclusion criteria included sepsis, concomitant
diagnosis of inflammatory bowel disease, irritable bowel syndrome, coeliac disease or malignancy.
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Written informed consent was obtained from all individual participants patients included in the
study. Patients were recruited as part of the FAMISHED study. Scientific and ethical approval was
acquired from the local Research and Development Office as well as Warwickshire Ethical committee
ref: 09/H1211/38. Demographic details are shown in Table 1.
Table 1. There were a total of 87 patients; with incomplete data on 15 patients hence this
table demonstrates demographics on the remaining 72 patients. OHA—oral hypoglycaemic agents;
HbA1c—glycated haemoglobin. HbA1C in normal subjects is 20–42 mmol/mol.
Demographic Data Diabetes Medication Frequency
Male (%) 44 (61) OHA 39
Female (%) 28 (39) Insulin 7
Mean age 56 OHA + Insulin 18
Median age 59 Nil 8
Mean BMI 39 HbA1c (mmol/mol)
Median BMI 39 Mean HbA1c 67
Median Hb A1c 57
2.2. Urine Collection, Storage and Transfer
Urine samples from patients with T2DM at UHCW NHS Trust were collected at clinic and stored
at ´80 ˝C within two hours of collection. They were transferred to the University of Warwick in a box
of dry ice. The samples were then defrosted in a laboratory fridge at 3 ˝C overnight prior to analysis.
2.3. FAIMS Analysis
For this study, a commercial FAIMS instrument was employed, specifically a Lonestar (Owlstone,
UK). FAIMS (or sometimes called Differentially Mobility Spectrometry—DMS), has been seen as a useful
means of separating gases and vapours since its conception in the 1980s [19]. They come in two basic
configurations using either a cylindrical or (as in our case) or planar design [20]. Such technology has
found favour in the security area for the detection of chemical warfare agents [21], but has been used for a
range of other applications either on its own or in combination with mass-spectrometry [22–24]. FAIMS
carries similar advantages in use to many electronic noses, it undertakes headspace analysis, it uses air as
the carrier gas, is relatively portable, is simple to operate, costs a similar amount to existing commercial
electronic noses and importantly, as it relies on a physical measurement of a chemical, it suffers less from
drift/poisoning than most electronic nose instruments. Sensitivity strongly depends on proton affinity
of the chemical of interest, but ranges between parts per million and parts per trillion [25] and in use
compares well with techniques such as GCMS [26]. It is worth noting that FAIMS is far more sensitive than
a standard GCMS system and the latter would require the use of a sophisticated pre-concentration system
(such as absorbent tubes) to reach similar sensitivity levels. FAIMS is composed of three stages, ionization,
filtration/separation and detection. In use, the sample headspace is drawn into the instrument (in our
case using a dynamic sampling methodology) where it is ionized (Ni-63 source) and mixed with a carrier
gas of clean/dry air. The total sample is then pushed between two separator plates to which an oscillating
asynchronous waveform is applied (up to GHz, with an amplitude up to hundreds of volts). The plates
are subjected to a high positive potential for a short period of time, followed by a small in magnitude
negative potential for a much longer period of time, but where the amplitude x time is the same in both
cases. The Lonestar uses a silicon based separator with a sub 50 µm electrode spacing to create very high
electric fields of up to 100 kV/cm. In use, the short/high potential is ramped through a series of values,
described as the “dispersion field” from 0 up to the systems maximum value. Ionised molecules that enter
the separation stage are then attracted, repelled or not affected by the electric field, depending upon the
mobility difference between high- and low-field regime (as shown in Figure 1). Any ion that touches one of
the separator plates, loses its charge and is not detected. However, those ions that pass between the plates
then exit the system where they collide with a detection plate and their charge measured. To increase the
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chemical detection range, a DC compensation voltage is applied to the plates, which is used to remove the
ion movement towards one of the plates. This compensation voltage (normally a single figure voltage) is
swept between a positive and negative potential and therefore for a certain compensation voltage, only
chemicals with a specific differential mobility will be detected. The mobility of an ion depends on the mass,
charge, size and shape since the field and the velocity are constant and are related by the equation below.
v “ KE (1)
where v and K are the velocity and mobility of ion respectively and E is the electric field strength. Since
velocity changes is not proportional to the electric field intensity variations, at higher electric fields the
ion mobility can be expressed by the following equation.











where Kh and K are the high-field mobility and low-field mobility respectively. α and β are compound
specific values which account for high-field mobility effect, N is carrier gas density number and E is
the electric field strength. More details of this process can be found in [25,27].
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ATLAS is a dynamic headspace sampler system that controls the sample temperature, sample 
agitation and the flow rate over the sample. This setup is commonly used for samples of this type by 
our group [10,11]. This heated the sample to 40 ± 0.1 °C. Each sample was tested three times 
sequentially, with each run having a flow rate over the sample of 200 mL/min of clean dry air. Further 
make-up air was added to create a total flow rate of 2 L/min. The FAIMS was scanned from 0 to 99% 
dispersion field in 51 steps, −6 V to +6 V compensation voltage in 512 steps and both positive and 
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possible paths depending on the molecules differential mobility.
2.4. Analysis Methodol gy
5 mL of urine ere aliquoted from each sample into a 10 mL glass vial and placed into an
ATLAS sample system (Owlstone, UK) attached to the front of the FAIMS, (Lonestar, Owlstone, UK).
The ATLAS is a dynamic headspace sampler system that controls the sample temperature, sample
agitation and the flow rate over the sample. This setup is commonly used for samples of this type
by our group [10,11]. This heated the sample to 40 ˘ 0.1 ˝C. Each sample was tested three times
sequentially, with each run having a flow rate over the sample of 200 mL/min of clean dry air. Further
make-up air was added to create a total flow rate of 2 L/min. The FAIMS was scanned from 0 to
99% dispersion field in 51 steps, ´6 V to +6 V compensation voltage in 512 steps and both positive
and negative ions were detected to create a test file composed of 52,224 data points. Figure 2 shows
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our experimental setup, with Figure 3 showing a typical output for a diabetic urine sample (positive
ions only).
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3. Results and Discussion
3.1. Results
In our initial analysis we considered the total chemical concentration (a mixture of gases and
volatile organic compounds). In FAIMS this is easily achieved by summing up all of the values at a
zero dispersion field (hence no separation). Figure 4 demonstrates the changes in urinary gas/volatile
concentration between 2009 and 2014, using this data. The graph shows that the total amount of
chemicals released decreases with sample age with more modern samples having a higher output. This
trend is confirmed in both the positive and negative electric fields of the FAIMS instrument depicted by
the red and green dots, respectively. We have also averaged the total output of positive and negative
ions to emphasis the changes over time, as shown in Table 2. It is worth noting that as the samples
get much older (greater than 3 years), the output increases once more, with an associated increase in
variance between the samples.
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Figure 4. Change in total number of urinary volatile organic compounds over time (from December
2009 to May 2014).
In addition to measuring the change in overall gas/volatile concentration, we also investigated
the chemical diversity of the samples. We define chemical diversity as a measure of the amount of
different chemicals in the sample, independent of concentration. As FAIMS separates chemicals based
on mobility, it is possible to measure the diversity of chemicals at a specific dispersion field, though
we are unable to separate chemicals with the same differential mobility. In our case, we took a 50%
dispersion field (selected as a compromise between chemical separation and measuring as many
chemical as possible), then used a threshold value of 0.01 to remove the background noise. This result
is shown in Figure 5. Again this result has been averaged into each year and is shown in Table 2.
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Table 2. Changes in output signal for both positive and negative ions as a function of time. Percentage
for year one taken as 100%.
Positive Ions (Arbitrary Units)
Year 2014 2013 2012 2011 2010 2009
Age (days) 0–147 148–503 504–859 860–1215 1216–1572 1572–1617
Average 68.2 67.0 57.0 53.4 62.3 63.4
s.d. 7.4 8.6 6.5 3.8 17.7 12.6
% 100.0 98.2 83.6 78.3 91.3 93.0
Negative Ions (Arbitrary Units)
Year 2014 2013 2012 2011 2010 2009
Age (days) 0–147 148–503 504–859 860–1215 1216–1572 1572–1617
Average ´58.4 ´58.2 ´48.5 ´44.9 ´48.6 ´44.7
s.d. 5.3 7.8 3.5 4.7 7.0 5.2
% 100.0 99.7 83.0 76.9 83.2 76.5
Threshold Values (Positive Ions Only)
Year 2014 2013 2012 2011 2010 2009
Age (days) 0–147 148–503 504–859 860–1215 1216–1572 1572–1617
Average 54.3 55.5 53.2 54.3 52.8 52.3
s.d. 2.3 2.2 2.2 1.8 2.1 1.5
% 100.0 102.2 98.0 100 97.2 96.3
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Figure 5. Che ical diversity of urinary volatile organic compounds over time (from December 2009 to
May 2014), with linear fit to emphasis output change.
Of note, there is less variation in the total number of emissions in the more recent samples with
greater uniformity and stability of concentrations together with tighter clustering of the total number
of chemicals released. This is particularly evident for the urine samples obtained from October 2013 to
May 2014, which demonstrates that the chemical information is stable for at least 9 months, as shown
in Figure 6 and Table 3. In the latter table, the data for 12 months is included and after a 9 month
period there data suggests a fall-off in chemical output. Some care should be taken due to the variance
in measurements, but there is a clear reduction in chemical output after 9 months.
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for low molecular weight gases dissolved in the sample. In addition, we may be observing water in
the urine evaporating as it ages with the subsequent release of water-soluble volatiles. For the very
old samples, we may be seeing bacterial activity that could be resulting in a higher chemical output,
as described in [8]. Finally, in our case, the samples are stored in standard plastic sterilin bottles,
commonly used by the medical profession. It may be possible that the plastic is absorbing volatiles
over time. This requires further investigation, but beyond the scope of this study.
From our experiments, we can tentatively propose a urine sample best before date of 12 months,
though ideally samples should be tested within 9. Analysis of the results shows that there is no
significant loss in chemicals over this 9 month period, but appears to increase relatively rapidly after
this. However, care should still be taken to ensure that when samples are collected from different
groups (disease and control) then samples should be collected at similar times and not be separated
by a significant period. We have found (unpublished results) that even fresh samples vs. 6 month
old samples could result in separation (using pattern recognition techniques) based on age instead
of disease.
Of final note, for samples taken over the first 9 months, the variation in chemical output and the
differences in chemical diversity only changes by around 10% across the samples. The diabetic patients
were under no dietary controls and urines were collected as spot samples. Though the samples were
from a single disease group, it is interesting that the differences in gender, age and diet only produced
a relatively small change in volatile output.
4. Conclusions
Gas phase biomarkers are becoming of ever increasing interest to researchers. One instrument
showing promise is the electronic nose—an instrument that attempts to mimic the biological olfactory
system by analyzing samples as a whole. Urine is an important sample type, due to its ease of collection
and clinical utility. However, when undertaking this type of research, the question of long-term stability
in storage becomes important, especially for diseases with low prevalence. Although in this study
samples were taken and analysed from those with diabetes and we did not track any specific biomarker
(which is difficult with the electronic nose), it is biologically plausible that these results could be used
to infer for diabetes and other medical conditions a possible storage time. Our results suggest that even
at ´80 ˝C, changes of total chemical concentrations are noticeable before 200 days, and continue over
time. Extrapolating our results would suggest that storage at ´20 ˝C would result in more rapid loss
of chemicals but remains uncertain at which time point the stored sample loses its diagnostic value.
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